Oral Antiviral Market By Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, Others), By Drug class (Protease inhibitors, Reverse transcriptase inhibitors, Others), By Distribution channel (Hospital pharmacies, Drug store and retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
The oral antiviral market size valued for $35,213.48 million in 2021 and is estimated to reach $43,394.00 million by 2031, exhibiting a CAGR of 2.1% from 2022 to 2031.
Antiviral drugs are a class of medicines particularly used for the treatment of viral infections. Specific antiviral drugs are used for treating specific type of viruses. Oral antiviral agents are medications that are taken by mouth to treat viral infections. In addition, antiviral drugs, unlike the most antibiotics, do not destroy their target pathogens; rather inhibit their development. Further, these drugs work by interfering with various stages of the viral life cycle, such as replication or assembly, reduce the severity and duration of symptoms, as well as reduce the spread of the virus to others. Moreover, many oral antiviral drugs are approved and available for treating viral infections such as baloxavir marboxil & zanamivir for influenza, ledipasvir-sofosbuvir for hepatitis and darunavir & lamivudine for human immunodeficiency virus (HIV).
The driving factors for oral antiviral market are rise in prevalence of viral infections such as influenza, human immunodeficiency virus (HIV) and hepatitis. For instance, according to the report of the Centers for Disease Control and Prevention (CDC) 2022, 9 million cases of influenza were reported, with 4 million medical visits and 10,000 hospitalizations. Thus, a rise in prevalence of influenza is expected to drive the growth of the market. In addition, rise in prevalence of hepatitis and herpes cases across the globe is anticipated to drive the growth of market. Further, increase in number of pipeline medications for treating viral infections that is anticipated to receive regulatory approval in the upcoming years; thus, driving the growth of market.
Furthermore, rise in initiatives by non-government & government organizations to increase awareness about the viral diseases and available oral treatment among the patients through different programs and campaigns is predicted to boost the growth of the market. In addition, rise in adoption of advanced technologies to diagnose viral diseases and awareness about the importance of early diagnosis of viral infections such as hepatitis and human immunodeficiency virus (HIV) is anticipated to boost the market growth. Furthermore, many key players have adopted key strategies such as collaboration, agreement, or alliance to increase their market presence in the global oral antiviral market, which is expected to drive the growth of the market.
However, factors such as the high cost of oral antivirals might restrain the growth of oral antiviral market. In addition, availability of vaccines for viral diseases such as influenza, hepatitis, human papillomavirus (HPV) and herpes is expected to hamper the growth of market. Moreover, rise in demand of novel therapeutics for treating viral infections and rise in regulatory approvals for antiviral drugs is expected to offer lucrative opportunities to key players of market.
The global oral antiviral market is segmented into indication, drug class, distribution channel, and region. On the basis of indication, the market is categorized into hepatitis, human immunodeficiency virus (HIV), influenza and others. On the basis of drug class, the market is categorized into protease inhibitors, reverse transcriptase inhibitors and others. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major Key players that operate in the global oral antiviral market are AbbVie Inc., Amneal Pharmaceuticals LLC, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline plc, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the oral antiviral market analysis from 2021 to 2031 to identify the prevailing oral antiviral market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the oral antiviral market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global oral antiviral market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Indication
Hepatitis
Human Immunodeficiency Virus (HIV)
Influenza
Others
By Drug class
Protease inhibitors
Reverse transcriptase inhibitors
Others
By Distribution channel
Hospital pharmacies
Drug store and retail pharmacies
Online providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
F. Hoffman-La Roche Ltd
Merck & Co., Inc.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
Amneal Pharmaceuticals LLC
Viatris Inc.
AbbVie Inc.
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increasing prevalence of viral infection
- 3.4.1.2. Increasing government initiatives regarding viral infections
- 3.4.1.3. Rise in approval of antiviral drugs
- 3.4.2. Restraints
- 3.4.2.1. Stringent regulatory requirements for the approval and commercialization of HIV drugs
- 3.4.3. Opportunities
- 3.4.3.1. Growth opportunities in emerging markets
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: ORAL ANTIVIRAL MARKET, BY INDICATION
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Hepatitis
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Human Immunodeficiency Virus (HIV)
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Influenza
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Others
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- CHAPTER 5: ORAL ANTIVIRAL MARKET, BY DRUG CLASS
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Protease inhibitors
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Reverse transcriptase inhibitors
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- CHAPTER 6: ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Drug store and retail pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: ORAL ANTIVIRAL MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Indication
- 7.2.3. Market size and forecast, by Drug class
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Indication
- 7.2.5.1.3. Market size and forecast, by Drug class
- 7.2.5.1.4. Market size and forecast, by Distribution channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Indication
- 7.2.5.2.3. Market size and forecast, by Drug class
- 7.2.5.2.4. Market size and forecast, by Distribution channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Indication
- 7.2.5.3.3. Market size and forecast, by Drug class
- 7.2.5.3.4. Market size and forecast, by Distribution channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Indication
- 7.3.3. Market size and forecast, by Drug class
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Indication
- 7.3.5.1.3. Market size and forecast, by Drug class
- 7.3.5.1.4. Market size and forecast, by Distribution channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Indication
- 7.3.5.2.3. Market size and forecast, by Drug class
- 7.3.5.2.4. Market size and forecast, by Distribution channel
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Indication
- 7.3.5.3.3. Market size and forecast, by Drug class
- 7.3.5.3.4. Market size and forecast, by Distribution channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Indication
- 7.3.5.4.3. Market size and forecast, by Drug class
- 7.3.5.4.4. Market size and forecast, by Distribution channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Indication
- 7.3.5.5.3. Market size and forecast, by Drug class
- 7.3.5.5.4. Market size and forecast, by Distribution channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Indication
- 7.3.5.6.3. Market size and forecast, by Drug class
- 7.3.5.6.4. Market size and forecast, by Distribution channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Indication
- 7.4.3. Market size and forecast, by Drug class
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Indication
- 7.4.5.1.3. Market size and forecast, by Drug class
- 7.4.5.1.4. Market size and forecast, by Distribution channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Indication
- 7.4.5.2.3. Market size and forecast, by Drug class
- 7.4.5.2.4. Market size and forecast, by Distribution channel
- 7.4.5.3. India
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Indication
- 7.4.5.3.3. Market size and forecast, by Drug class
- 7.4.5.3.4. Market size and forecast, by Distribution channel
- 7.4.5.4. Australia
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Indication
- 7.4.5.4.3. Market size and forecast, by Drug class
- 7.4.5.4.4. Market size and forecast, by Distribution channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Indication
- 7.4.5.5.3. Market size and forecast, by Drug class
- 7.4.5.5.4. Market size and forecast, by Distribution channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Indication
- 7.4.5.6.3. Market size and forecast, by Drug class
- 7.4.5.6.4. Market size and forecast, by Distribution channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Indication
- 7.5.3. Market size and forecast, by Drug class
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Indication
- 7.5.5.1.3. Market size and forecast, by Drug class
- 7.5.5.1.4. Market size and forecast, by Distribution channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Indication
- 7.5.5.2.3. Market size and forecast, by Drug class
- 7.5.5.2.4. Market size and forecast, by Distribution channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Indication
- 7.5.5.3.3. Market size and forecast, by Drug class
- 7.5.5.3.4. Market size and forecast, by Distribution channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Indication
- 7.5.5.4.3. Market size and forecast, by Drug class
- 7.5.5.4.4. Market size and forecast, by Distribution channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2021
- CHAPTER 9: COMPANY PROFILES
- 9.1. Gilead Sciences, Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. F. Hoffmann-La Roche Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Merck & Co., Inc.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. AbbVie Inc.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. GlaxoSmithKline plc
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Bristol-Myers Squibb Company
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Johnson & Johnson
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Viatris Inc.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Amneal Pharmaceuticals LLC
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- LIST OF TABLES
- TABLE 01. GLOBAL ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 02. ORAL ANTIVIRAL MARKET FOR HEPATITIS, BY REGION, 2021-2031 ($MILLION)
- TABLE 03. ORAL ANTIVIRAL MARKET FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2021-2031 ($MILLION)
- TABLE 04. ORAL ANTIVIRAL MARKET FOR INFLUENZA, BY REGION, 2021-2031 ($MILLION)
- TABLE 05. ORAL ANTIVIRAL MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 06. GLOBAL ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 07. ORAL ANTIVIRAL MARKET FOR PROTEASE INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 08. ORAL ANTIVIRAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 09. ORAL ANTIVIRAL MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. GLOBAL ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 11. ORAL ANTIVIRAL MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. ORAL ANTIVIRAL MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. ORAL ANTIVIRAL MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. ORAL ANTIVIRAL MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. NORTH AMERICA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 16. NORTH AMERICA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 17. NORTH AMERICA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 18. NORTH AMERICA ORAL ANTIVIRAL MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. U.S. ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 20. U.S. ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 21. U.S. ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 22. CANADA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 23. CANADA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 24. CANADA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 25. MEXICO ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 26. MEXICO ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 27. MEXICO ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 28. EUROPE ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 29. EUROPE ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 30. EUROPE ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 31. EUROPE ORAL ANTIVIRAL MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 32. GERMANY ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 33. GERMANY ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 34. GERMANY ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 35. FRANCE ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 36. FRANCE ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 37. FRANCE ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 38. UK ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 39. UK ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 40. UK ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 41. ITALY ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 42. ITALY ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 43. ITALY ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 44. SPAIN ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 45. SPAIN ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 46. SPAIN ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 47. REST OF EUROPE ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 48. REST OF EUROPE ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 49. REST OF EUROPE ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 50. ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 51. ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 52. ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 53. ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 54. JAPAN ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 55. JAPAN ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 56. JAPAN ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 57. CHINA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 58. CHINA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 59. CHINA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 60. INDIA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 61. INDIA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 62. INDIA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 63. AUSTRALIA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 64. AUSTRALIA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 65. AUSTRALIA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 66. SOUTH KOREA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 67. SOUTH KOREA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 68. SOUTH KOREA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 70. REST OF ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 71. REST OF ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 72. LAMEA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 73. LAMEA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 74. LAMEA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 75. LAMEA ORAL ANTIVIRAL MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 76. BRAZIL ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 77. BRAZIL ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 78. BRAZIL ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 79. SAUDI ARABIA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 80. SAUDI ARABIA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 81. SAUDI ARABIA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 82. SOUTH AFRICA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 83. SOUTH AFRICA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 84. SOUTH AFRICA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 85. REST OF LAMEA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
- TABLE 86. REST OF LAMEA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
- TABLE 87. REST OF LAMEA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 88. GILEAD SCIENCES, INC.: KEY EXECUTIVES
- TABLE 89. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 90. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
- TABLE 91. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 92. GILEAD SCIENCES, INC.: KEY STRATERGIES
- TABLE 93. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 94. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 95. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
- TABLE 96. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 97. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
- TABLE 98. MERCK & CO., INC.: KEY EXECUTIVES
- TABLE 99. MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 100. MERCK & CO., INC.: PRODUCT SEGMENTS
- TABLE 101. MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 102. ABBVIE INC.: KEY EXECUTIVES
- TABLE 103. ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 104. ABBVIE INC.: PRODUCT SEGMENTS
- TABLE 105. ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 106. ABBVIE INC.: KEY STRATERGIES
- TABLE 107. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
- TABLE 108. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 109. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
- TABLE 110. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 111. GLAXOSMITHKLINE PLC: KEY STRATERGIES
- TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
- TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 114. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
- TABLE 115. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- TABLE 116. JOHNSON & JOHNSON: KEY EXECUTIVES
- TABLE 117. JOHNSON & JOHNSON: COMPANY SNAPSHOT
- TABLE 118. JOHNSON & JOHNSON: PRODUCT SEGMENTS
- TABLE 119. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
- TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 124. VIATRIS INC.: KEY EXECUTIVES
- TABLE 125. VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 126. VIATRIS INC.: PRODUCT SEGMENTS
- TABLE 127. VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 128. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
- TABLE 129. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
- TABLE 130. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
- TABLE 131. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. ORAL ANTIVIRAL MARKET, 2021-2031
- FIGURE 02. SEGMENTATION OF ORAL ANTIVIRAL MARKET, 2021-2031
- FIGURE 03. TOP INVESTMENT POCKETS IN ORAL ANTIVIRAL MARKET (2022-2031)
- FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 05. LOW BARGAINING POWER OF BUYERS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALORAL ANTIVIRAL MARKET
- FIGURE 10. ORAL ANTIVIRAL MARKET, BY INDICATION, 2021(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR HEPATITIS, BY COUNTRY 2021-2031(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY COUNTRY 2021-2031(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR INFLUENZA, BY COUNTRY 2021-2031(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
- FIGURE 15. ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR PROTEASE INHIBITORS, BY COUNTRY 2021-2031(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY 2021-2031(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
- FIGURE 19. ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
- FIGURE 23. ORAL ANTIVIRAL MARKET BY REGION, 2021
- FIGURE 24. U.S. ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 25. CANADA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 26. MEXICO ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 27. GERMANY ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 28. FRANCE ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 29. UK ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 30. ITALY ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 31. SPAIN ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 32. REST OF EUROPE ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 33. JAPAN ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 34. CHINA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 35. INDIA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 36. AUSTRALIA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 37. SOUTH KOREA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 38. REST OF ASIA-PACIFIC ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 39. BRAZIL ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 40. SAUDI ARABIA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 41. SOUTH AFRICA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 42. REST OF LAMEA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
- FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 47. COMPETITIVE DASHBOARD
- FIGURE 48. COMPETITIVE HEATMAP: ORAL ANTIVIRAL MARKET
- FIGURE 49. TOP PLAYER POSITIONING, 2021
- FIGURE 50. GILEAD SCIENCES, INC.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 54. MERCK & CO., INC.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 55. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 56. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 57. ABBVIE INC.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 58. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 59. ABBVIE INC.: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 60. GLAXOSMITHKLINE PLC: NET SALES, 2019-2021 ($MILLION)
- FIGURE 61. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 62. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 63. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2019-2021 ($MILLION)
- FIGURE 64. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 65. JOHNSON & JOHNSON: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 66. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 67. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 69. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
- FIGURE 70. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
- FIGURE 71. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 72. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
- FIGURE 73. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook